got pregnant on semaglutide and Conception: Safety, Timing & Planning The 'Oopzempic' baby boom: Rise

This study, combined with the earlier real-world data presented at key conferences, reinforces GIMOTI's potential to improve outcomes for patients and reduce the overall financial burden on the healthcare system." The study's specific cohort consisted of 92 total patients between the nasal metoclopramide (NMCP, N=51) and oral metoclopramide (OMCP, N=41) groups

But the timeline can vary depending on the type of Wegovy skin problem youre having

Funding This work was funded by a sponsored agreement from Lonza to Fielding

Whether the more rare adverse events differ between the different agents can only be answered by using observational cohort data from a very large group of patients and a longer follow-up time

PMID 13642195